Compare HLLY & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLLY | AURA |
|---|---|---|
| Founded | 1903 | 2007 |
| Country | United States | United States |
| Employees | 1520 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.2M | 377.2M |
| IPO Year | N/A | 2021 |
| Metric | HLLY | AURA |
|---|---|---|
| Price | $2.87 | $6.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $4.57 | ★ $20.20 |
| AVG Volume (30 Days) | ★ 986.7K | 235.8K |
| Earning Date | 03-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $4.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $4.73 |
| 52 Week High | $4.48 | $7.48 |
| Indicator | HLLY | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 33.88 | 52.96 |
| Support Level | $2.72 | $5.83 |
| Resistance Level | $3.09 | $6.78 |
| Average True Range (ATR) | 0.16 | 0.40 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 29.01 | 54.34 |
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.